DDInter1267 DDInter1376
Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Naratriptan {u} (Compound) resembles {v} (Compound) Sumatriptan
Naratriptan {u} (Compound) binds {v} (Gene) HTR1A
Naratriptan {u} (Compound) palliates {v} (Disease) migraine
Naratriptan {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 1d Receptor Agonists
Naratriptan {u} (Compound) causes {v} (Side Effect) Parathyroid tumour
Naratriptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Naratriptan {u} may lead to a major life threatening interaction when taken with {v} Dolasetron
Naratriptan {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Naratriptan (Compound) resembles Sumatriptan (Compound)
Naratriptan (Compound) binds HTR1A (Gene)
Naratriptan (Compound) palliates migraine (Disease)
Naratriptan (Compound) is included by Serotonin 1d Receptor Agonists (Pharmacologic Class)
Naratriptan (Compound) causes Parathyroid tumour (Side Effect)
Naratriptan may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Naratriptan may lead to a major life threatening interaction when taken with Dolasetron
Naratriptan may lead to a major life threatening interaction when taken with Sibutramine